It’s been a brutal year for cannabis investors, with the ETF MANAGERS TR/TIERRA XP LATIN AME MJ down another 1.2% this month ahead of a series of major cannabis earnings reports this week.
Cronos Group Inc CRON shares traded just 1.2% higher on Tuesday morning after reporting 238% revenue growth in the third quarter, but cannabis short sellers are still sitting on large November gains as cannabis earnings season kicks off.
Short sellers have aggressively piled into the cannabis space in 2019, with short interest up 39% this year to $4.1 billion.
Short sellers are paying a steep price to bet against cannabis, with the average cost to borrow at 21.6% for cannabis stocks.
Tilray Inc TLRY is the most expensive cannabis stock, with a 58.8% U.S. borrow fee.
Canopy Growth Corp CGC shares are now down 24.4% year-to-date, making Canopy the most profitable cannabis short of 2019. Canopy shorts are up $309 million year-to-date ahead of third-quarter earnings.
In November alone, cannabis short sellers have earned $190 million in profits.
Short Squeeze In Play?
Given the year-to-date gains, S3 Partners analyst Ihor Dusaniwsky said cannabis short sellers have no reason to cover their short positions at this point.
In the past month, short sellers have added more than $20 million each to their positions in Canopy and Aphria Inc APHA alone.
“If sector wide price weakness continues, we should seea continued slow and steady increase of short selling in the cannabis sector,” Dusaniwsky said in a Nov. 8 report.
The following are the five largest cannabis short positions ahead of this week’s earnings reports:
- Canopy Growth: $1.03 billion in short interest.
- Aurora Cannabis Inc ACB: $670.7 million in short interest.
- GW Pharmaceuticals PLC- ADR GWPH: $561.9 million in short interest.
- Cronos: $389.7 million in short interest.
- Tilray: $195.7 million in short interest.
Benzinga's Take
Cannabis stocks will likely continue to be volatile in the near-term while the industry matures. Both long buyers and short sellers should understand bets on individual stocks in either direction remain high-risk, high-reward plays at this stage.
Do you agree with this take? Email feedback@benzinga.com with your thoughts.
Related Links:
Is Cannabis The Liquor Industry's Worst Nightmare?
Large Option Trader Betting On Canopy Growth Bounce Ahead Of Earnings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.